Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...
The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted ...
Natal, alarming gaps between scientific advancements and community behaviour persist. This article explores the critical need ...
This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...
(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback